OpenNashEarnings

Health Insurance · NYSE: MOH

Molina Healthcare earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 4 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Molina went live on its $6 billion Florida CMS contract while exiting traditional MAPD and shrinking Marketplace to seven states, narrowing the business around Medicaid and dual-eligible Medicare.

Molina's membership is shrinking in Medicaid and Marketplace, but the business is being reshaped around Medicaid and dual-eligible Medicare. The Florida CMS contract for medically complex children started in the fourth quarter, with about 115,000 members. Management is exiting its traditional Medicare Advantage Prescription Drug (MAPD) product for 2027, and Marketplace is shrinking to seven states. The dual-eligible Medicare business performed well.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$11.1B−3.4% y/yQ3 2026
Q4 2024: $10.5B (worked out from the annual figure)Q4 ’24$10.5BQ1 2025: $11.1BQ1 ’25$11.1BQ2 2025: $11.4BQ2 ’25$11.4BQ3 2025: $11.5BQ3 ’25$11.5BQ4 2025: $11.4B (worked out from the annual figure)Q4 ’25$11.4BQ1 2026: $10.8BQ1 ’26$10.8BQ2 2026: $10.9BQ2 ’26$10.9BQ3 2026: $11.1BQ3 ’26$11.1B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$10.5B *
Q1 2025$11.1B
Q2 2025$11.4B
Q3 2025$11.5B
Q4 2025$11.4B *
Q1 2026$10.8B
Q2 2026$10.9B
Q3 2026$11.1B
Diluted EPS (GAAP)$0.73−51.7% y/yQ3 2026
Q1 2025: $5.45Q1 ’25$5.45Q2 2025: $4.75Q2 ’25$4.75Q3 2025: $1.51Q3 ’25$1.51Q1 2026: $0.27Q1 ’26$0.27Q2 2026: $1.19Q2 ’26$1.19Q3 2026: $0.73Q3 ’26$0.73
Data
Q1 2025$5.45
Q2 2025$4.75
Q3 2025$1.51
Q1 2026$0.27
Q2 2026$1.19
Q3 2026$0.73

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.0%−0.2 pts y/yQ3 2026
Q4 2024: 3.6%Q4 ’243.6%Q1 2025: 3.9%Q1 ’253.9%Q2 2025: 3.3%Q2 ’253.3%Q3 2025: 1.2%Q3 ’251.2%Q4 2025: -1.4%Q4 ’25-1.4%Q1 2026: 0.8%Q1 ’260.8%Q2 2026: 1.3%Q2 ’261.3%Q3 2026: 1.0%Q3 ’261.0%
Data
Q4 20243.6%
Q1 20253.9%
Q2 20253.3%
Q3 20251.2%
Q4 2025-1.4%
Q1 20260.8%
Q2 20261.3%
Q3 20261.0%
Free cash flow-$196.0M−20.2% y/yQ3 2026
Q4 2024: -$235.0MQ4 ’24-$235.0MQ1 2025: $168.0MQ1 ’25$168.0MQ2 2025: -$344.0MQ2 ’25-$344.0MQ3 2025: -$163.0MQ3 ’25-$163.0MQ4 2025: -$297.0MQ4 ’25-$297.0MQ1 2026: $1.1BQ1 ’26$1.1BQ2 2026: -$324.0MQ2 ’26-$324.0MQ3 2026: -$196.0MQ3 ’26-$196.0M
Data
Q4 2024-$235.0M
Q1 2025$168.0M
Q2 2025-$344.0M
Q3 2025-$163.0M
Q4 2025-$297.0M
Q1 2026$1.1B
Q2 2026-$324.0M
Q3 2026-$196.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$10.5Bd$11.1B$11.4B$11.5B$11.4Bd$10.8B$10.9B$11.1B
Operating income$380.0Md$433.0M$373.0M$137.0M-$162.0Md$83.0M$145.0M$106.0M
Operating margin3.6%3.9%3.3%1.2%-1.4%0.8%1.3%1.0%
Net income$251.0Md$298.0M$255.0M$79.0M-$160.0Md$14.0M$60.0M$38.0M
Diluted EPS—$5.45$4.75$1.51—$0.27$1.19$0.73
Operating cash flow-$224.0Md$190.0M-$302.0Md-$125.0Md-$298.0Md$1.1B-$294.0Md-$159.0Md
Capital expenditure$11.0Md$22.0M$42.0Md$38.0Md-$1.0Md$27.0M$30.0Md$37.0Md
Free cash flow-$235.0M$168.0M-$344.0M-$163.0M-$297.0M$1.1B-$324.0M-$196.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings